Added value of regional 18F-FDG PET/MRI-assisted whole-body 18F-FDG PET/CT in malignant ascites with unknown primary origin
Tóm tắt
Comparing to PET/CT, integrative PET/MRI imaging provides superior soft tissue resolution. This study aims to evaluate the added value of regional delayed 18F-FDG PET/MRI-assisted whole-body 18F-FDG PET/CT in diagnosing malignant ascites patients. The final diagnosis included 22 patients with ovarian cancer (n = 11), peritoneal cancer (n = 3), colon cancer (n = 2), liver cancer (n = 2), pancreatic cancer (n = 2), gastric cancer (n = 1), and fallopian tube cancer (n = 1). The diagnosis of the primary tumor using whole-body PET/CT was correct in 11 cases. Regional PET/MRI-assisted whole-body PET/CT diagnosis was correct in 18 cases, including 6 more cases of ovarian cancer and 1 more case of fallopian tube cancer. Among 4 cases that were not diagnosed correctly, 1 case had the primary tumor outside of the PET/MRI scan area, 2 cases were peritoneal cancer, and 1 case was colon cancer. The diagnostic accuracy of regional PET/MRI-assisted whole-body PET/CT was higher than PET/CT alone (81.8% vs. 50.0%, κ 2 = 5.14, p = 0.023). The primary tumor conspicuity score of PET/MRI was higher than PET/CT (3.67 ± 0.66 vs. 2.76 ± 0.94, P < 0.01). In the same scan area, more metastases were detected in PET/MRI than in PET/CT (156 vs. 86 in total, and 7.43 ± 5.17 vs. 4.10 ± 1.92 per patient, t = 3.89, P < 0.01). Lesion-to-background ratio in PET/MRI was higher than that in PET/CT (10.76 ± 5.16 vs. 6.56 ± 3.45, t = 13.02, P < 0.01). Comparing to whole-body PET/CT alone, additional delayed regional PET/MRI with high soft tissue resolution is helpful in diagnosing the location of the primary tumor and identifying more metastases in patients with malignant ascites. Yet larger sample size in multicenter and prospective clinical researches is still needed.
Từ khóa
Tài liệu tham khảo
Adam RA, Adam YG (2004) Malignant ascites: past, present, and future. J Am Coll Surg 198(6):999–1011
Ambrosini V, Nanni C, Rubello D, Moretti A, Battista G, Castellucci P et al (2006) 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 111(8):1146–1155
Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18(5):945–949
Bagade S, Fowler KJ, Schwarz JK, Grigsby PW, Dehdashti F (2015) PET/MRI evaluation of gynecologic malignancies and prostate cancer. Semin Nucl Med 45(4):293–303
Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42(5):589–597
Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P et al (2015) [F-18]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol I 42(1):56–65
Chan WL, Ramsay SC, Szeto ER, Freund J, Pohlen JM, Tarlinton LC et al (2011) Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy. J Med Imaging Radiat Oncol 55(4):379–390
Czernin J, Ta L, Herrmann K (2014) Does PET/MR imaging improve cancer assessments? Literature evidence from more than 900 patients. J Nucl Med 55(Supplement 2):59S-62S
Drzezga A, Souvatzoglou M, Eiber M, Beer AJ, Furst S, Martinez-Moller A et al (2012) First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med 53(6):845–855
Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ et al (2017) PET/MRI: where might it replace PET/CT? J Magn Reson Imaging 46(5):1247–1262
Fujii S, Matsusue E, Kanasaki Y, Kanamori Y, Nakanishi J, Sugihara S et al (2008) Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 18(1):18–23
Galgano SJ, Calderone CE, Xie C, Smith EN, Porter KK, McConathy JE (2021) Applications of PET/MRI in abdominopelvic oncology. Radiographics 41(6):1750–1765
Han N, Sun X, Qin C, Hassan Bakari K, Wu Z, Zhang Y et al (2018) Value of (18)F-FDG PET/CT combined with tumor markers in the evaluation of ascites. AJR Am J Roentgenol 210(5):1155–1163
Kim SK, Choi HJ, Park SY, Lee HY, Seo SS, Yoo CW et al (2009) Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer 45(12):2103–2109
Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13(4):273–282
Levy AD, Arnaiz J, Shaw JC, Sobin LH (2008) From the archives of the AFIP: primary peritoneal tumors: imaging features with pathologic correlation. Radiographics 28(2):583–607
Low RN, Sebrechts CP, Barone RM, Muller W (2009) Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings-a feasibility study. Am J Roentgenol 193(2):461–470
Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S et al (2005) Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging 32(5):589–592
Niekel MC, Bipat S, Stoker J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257(3):674–684
Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261(3):700–718
Podoloff DA (2009) PET/CT and occult primary tumors. J Natl Compr Canc Netw 7(3):239–244
Saif MW, Siddiqui IAR, Sohail MA (2009) Management of ascites due to gastrointestinal malignancy. Ann Saudi Med 29(5):369–377
Schwenzer NF, Schmidt H, Claussen CD (2012) Whole-body MR/PET: applications in abdominal imaging. Abdom Imaging 37(1):20–28
Sekine T, Barbosa FG, Sah BR, Mader CE, Delso G, Burger IA et al (2017) PET/MR outperforms PET/CT in suspected occult tumors. Clin Nucl Med 42(2):e88–e95
Spick C, Herrmann K, Czernin J (2016) 18F-FDG PET/CT and PET/MRI perform equally well in cancer: Evidence from studies on more than 2,300 patients. J Nucl Med 57(3):420–430
Xin J, Ma Q, Guo Q, Sun H, Zhang S, Liu C et al (2016) PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer. Eur J Radiol 85(4):751–759
Yang HL, Liu T, Wang XM, Xu Y, Deng SM (2011) Diagnosis of bone metastases: a meta-analysis comparing (1)(8)FDG PET, CT, MRI and bone scintigraphy. Eur Radiol 21(12):2604–2617
Yong TW, Yuan ZZ, Jun Z, Lin Z, He WZ, Juanqi Z (2011) Sensitivity of PET/MR images in liver metastases from colorectal carcinoma. Hell J Nucl Med 14(3):264–268
Zhang M, Jiang X, Zhang M, Xu H, Zhai G, Li B (2009) The role of 18F-FDG PET/CT in the evaluation of ascites of undetermined origin. J Nucl Med 50(4):506–512
Zhou N, Meng X, Zhang Y, Yu B, Yuan J, Yu J et al (2021) Diagnostic value of delayed PET/MR in liver metastasis in comparison with PET/CT. Front Oncol 11:717687